Free cash flow margin ranged from 11.5% to 29.8% with the latest reading at 18.1%, driven heavily by working capital timing that swung from a $173.3 million outflow to a $158.6 million inflow within two quarters, while acquisition outflows of $359.4 million in Q3 2026 indicate free cash flow is being largely deployed into M&A rather than retained.
Zimmer Biomet Holdings, Inc. (ZBH) cash flow statement — 27-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 |
|---|
| Cash from Operations | 1.88B | 1.7B | 1.5B | 1.58B | 1.28B | 1.5B | 1.2B | 1.59B | 1.75B | 1.58B | 1.63B | 849.8M | 1.06B | 963.1M | 1.15B | 1.18B | 1.19B | 1.12B | 1.04B | 1.08B | 1.04B | 878.2M | 862.2M | 494.8M | 220.2M | 171.8M | 232.4M | 180M |
| Operating CF Margin % | - | 20.62% | 19.53% | 21.39% | 18.51% | 21.96% | 19.66% | 19.87% | 22.03% | 20.28% | 21.28% | 14.17% | 22.69% | 20.83% | 25.76% | 26.44% | 28.28% | 27.29% | 25.19% | 27.82% | 29.77% | 26.72% | 28.92% | 26.03% | 16.04% | 14.58% | 22.33% | 19.17% |
| Operating CF Growth % | 48.23% | 13.19% | -5.2% | 23.11% | -14.31% | 24.47% | -24.04% | -9.25% | 10.43% | -3.06% | 92.07% | -19.87% | 10.11% | -16.39% | -2.12% | -1.39% | 6.8% | 7.65% | -4.27% | 4.2% | 18.5% | 1.86% | 74.25% | 124.7% | 28.17% | -26.08% | 29.11% | - |
| Net Income | 767.5M | 705.1M | 905.2M | 1.03B | 291.2M | 445.5M | -9.2M | 1.13B | -379.3M | 1.81B | 304.6M | 146.2M | 719.2M | 778.6M | 752.9M | 760M | 596.9M | 717.4M | 848.6M | 773.2M | 834.5M | 732.5M | 541.8M | 346.3M | 257.8M | 149.8M | 176M | 150M |
| Depreciation & Amortization | 1.11B | 1.09B | 996.3M | 951.7M | 926.4M | 937.7M | 898.4M | 1.01B | 1.04B | 1.06B | 1.04B | 712.4M | 375.8M | 358.5M | 363.1M | 359.9M | 340.2M | 337.4M | 275.1M | 230M | 197.4M | 185.7M | 181.3M | 103.3M | 25.3M | 23.4M | 23.1M | 22M |
| Stock-Based Compensation | 97.1M | 90.2M | 101M | 99.8M | 105M | 76M | 73.8M | 84.3M | 65.5M | 53.7M | 57.3M | 46.4M | 49.4M | 48.5M | 55M | 60.5M | 62M | 75.3M | 69.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -87.2M | -87.2M | -47.7M | -96.3M | -64.4M | -102.1M | 39.4M | -538.7M | 13.4M | -1.78B | -153.2M | -164M | -90.5M | -126.2M | -64.8M | -19.7M | -72.5M | -19.7M | 2M | 63.9M | 0 | 0 | 0 | 0 | 0 | 0 | 7.8M | 0 |
| Other Non-Cash Items | -1.5M | 100K | 0 | -2.5M | 337.9M | 276.3M | 631.9M | 70.1M | 979.7M | 364.3M | 407.7M | 399.4M | -5.7M | 37.8M | 109.1M | 19.3M | 208.3M | 56.5M | 12.7M | 84.4M | 79.6M | 39.3M | 59.4M | -35.2M | 29.9M | 1.1M | 5.3M | -9.5M |
| Working Capital Changes | -900K | -104.9M | -455.4M | -396.2M | -311.4M | -134.2M | -429.8M | -167.5M | 27.6M | 64.2M | -23.5M | -290.6M | 12.3M | -134.1M | -63.4M | -3.1M | 58.6M | -49.4M | -170.2M | -67.1M | -70.8M | -79.3M | 79.7M | 80.4M | -92.8M | -2.5M | 20.2M | 17.5M |
| Change in Receivables | -160.6M | -127.3M | -89.7M | -51.9M | -184.7M | -40.8M | -66.2M | -93.8M | 213.6M | 161.7M | -141.6M | -56.1M | -40.4M | -74.3M | -45.5M | -63.2M | -33M | -4.6M | -44.4M | -12.5M | -76.9M | -35.3M | -10.6M | -39M | -25M | 2.6M | 7.8M | 0 |
| Change in Inventory | 53.1M | 98.2M | 49.9M | -240.4M | -75.6M | -8.4M | -34.5M | -125.2M | -199.5M | -120.1M | 77.9M | -205.4M | -164.6M | -148.1M | -67.5M | 7.2M | 25.8M | 36.2M | -148.1M | -58M | -39.2M | -79.2M | -44.7M | -53M | -59.7M | -50.2M | -2.1M | 0 |
| Change in Payables | 234.5M | 101.8M | -322M | -55.3M | 103M | 86.5M | -95.1M | -42M | 155.9M | -133.3M | 32.6M | -252M | 116.1M | 33.6M | 47.8M | 20M | -800K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -1.22B | -1.98B | -888.1M | -778.9M | -529.2M | -503.6M | -613.8M | -729.3M | -416.6M | -510.8M | -1.69B | -7.56B | -469.4M | -282.5M | -592.1M | -624.4M | -726.9M | -381.2M | -924.2M | -491.5M | -287M | -311.1M | -388.3M | -1.1B | -35.7M | -54.7M | -29M | -33M |
| Capital Expenditures | -136.7M | -224.5M | -203.8M | -291.1M | -187.9M | -143.6M | -111.9M | -207.1M | -162.7M | -156M | -184.7M | -167.7M | -144.9M | -100M | -114.7M | -113.8M | -79.2M | -228.8M | -487.9M | -331.2M | -268.3M | -105.3M | -100.8M | -158.5M | -33.7M | -54.7M | -29M | -33M |
| CapEx % of Revenue | 1.6% | 2.73% | 2.65% | 3.94% | 2.71% | 2.1% | 1.83% | 2.59% | 2.05% | 2% | 2.41% | 2.8% | 3.1% | 2.16% | 2.56% | 2.56% | 1.88% | 5.59% | 11.84% | 8.5% | 7.68% | 3.2% | 3.38% | 8.34% | 2.46% | 4.64% | 2.79% | 3.51% |
| Acquisitions | -526.3M | -1.39B | -276.3M | -134.9M | -99.8M | 0 | -227.1M | -37.1M | -15.3M | -4M | -1.44B | -7.76B | -54.3M | -74.2M | -59M | -56.8M | -82.6M | -39.5M | -381.8M | -160.3M | -28.1M | -44.1M | -171.3M | -927.7M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -93.9M | -57.5M | -189.8M | -74.6M | -72.6M | -88.3M | -69.3M | -217.3M | -31.5M | -13.8M | -3M | 48.2M | -4.1M | -13.5M | -17.9M | -31.1M | -26.8M | -35.8M | -109.4M | 0 | 9.4M | -11.7M | -116.2M | -16.5M | -2M | 0 | 0 | 0 |
| Cash from Financing | -1.56B | 326M | -484.5M | -763.5M | -843.8M | -1.31B | -421.8M | -779.9M | -1.3B | -1.21B | -743.2M | 7.14B | -562.4M | -467.3M | -436.5M | -455.8M | -489.6M | -262.1M | -343.5M | -399.5M | -730.7M | -484.6M | -402M | 664.8M | -188.9M | -99.1M | -203.4M | -147M |
| Debt Issued (Net) | -480M | 1.03B | 536.3M | 54.6M | -1.06B | -1.05B | -252.9M | -716.1M | -1.15B | -1.25B | -259.6M | 7.37B | -247.7M | -97.5M | 97.2M | 549.8M | -2.2M | 660.3M | 330M | 0 | 18.8M | -555.3M | -461.4M | 620.6M | -212.8M | 366.3M | 0 | 0 |
| Equity Issued (Net) | -801.8M | -447.3M | -868M | -692.2M | -126.4M | 122.5M | 0 | 0 | 0 | 0 | -415.5M | -150M | -400.9M | -720.8M | -485.6M | -1.05B | -505.6M | -914.2M | -680M | -426.5M | -757.5M | 72.6M | 65M | 70.5M | 23.9M | 1.4M | 0 | 0 |
| Dividends Paid | -186.7M | -190.3M | -196M | -200.9M | -201.2M | -200.1M | -198.5M | -196.7M | -195.2M | -193.6M | -188.4M | -157.1M | -145.5M | -132.4M | -94.4M | -510.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -290M | 0 | 0 |
| Share Repurchases | -829.3M | -487M | -868M | -692.2M | -126.4M | 0 | 0 | 0 | 0 | 0 | -415.5M | -150M | -400.9M | -720.8M | -485.6M | -1.05B | -505.6M | -923.7M | -737M | -576.3M | -798.8M | -4.1M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -96.1M | -65.5M | 43.2M | 75M | 544.5M | -173.4M | 29.6M | 132.9M | 47.4M | 231.3M | 120.3M | 47.5M | 224M | 483.4M | 46.3M | 44.4M | 18.2M | -8.2M | 6.5M | 27M | 8M | -1.9M | -5.6M | -26.3M | 0 | -176.8M | -203.4M | -147M |
| Net Change in Cash | -892.8M | 66.4M | 109.7M | 40.1M | -102.8M | -323.6M | 184.2M | 75.1M | 18.4M | -109.7M | -825.2M | 369.3M | 2.7M | 196.3M | 116M | 99.4M | -22.8M | 479.1M | -251.3M | 198.2M | 32.5M | 78.6M | 77.1M | 61.8M | -2.7M | 18.4M | 0 | 0 |
| Free Cash Flow | 1.66B | 1.47B | 1.14B | 1.19B | 1.07B | 1.35B | 1.09B | 1.18B | 1.58B | 1.43B | 1.45B | 682.1M | 915.6M | 863.1M | 1.04B | 1.06B | 1.11B | 852.9M | 440.8M | 753.2M | 772.4M | 772.9M | 761.4M | 336.3M | 186.5M | 117.1M | 203.4M | 147M |
| FCF Margin % | 19.33% | 17.89% | 14.88% | 16.05% | 15.38% | 19.73% | 17.83% | 14.8% | 19.98% | 18.28% | 18.88% | 11.37% | 19.59% | 18.67% | 23.19% | 23.88% | 26.2% | 20.83% | 10.7% | 19.33% | 22.1% | 23.52% | 25.54% | 17.69% | 13.59% | 9.94% | 19.55% | 15.65% |
| FCF Growth % | 3.47% | 28.88% | -3.75% | 11.25% | -20.79% | 23.3% | -7.49% | -25.47% | 11.11% | -1.46% | 112.21% | -25.5% | 6.08% | -16.79% | -2.44% | -3.86% | 29.65% | 93.49% | -41.48% | -2.49% | -0.06% | 1.51% | 126.4% | 80.32% | 59.27% | -42.43% | 38.37% | - |
| FCF per Share | 8.66 | 7.41 | 5.60 | 5.66 | 5.07 | 6.22 | 5.12 | 5.55 | 7.56 | 6.80 | 6.94 | 3.59 | 5.33 | 5.02 | 5.89 | 5.63 | 5.50 | 3.95 | 1.93 | 3.17 | 3.15 | 3.09 | 3.07 | 1.59 | 0.95 | 0.60 | 1.05 | 0.76 |
| FCF Conversion (FCF/Net Income) | 2.16x | 2.41x | 1.66x | 1.54x | 5.55x | 3.73x | -8.67x | 1.40x | -4.61x | 0.87x | 5.34x | 5.78x | 1.47x | 1.27x | 1.53x | 1.55x | 2.00x | 1.56x | 1.22x | 1.40x | 1.25x | 1.20x | 1.59x | 1.43x | 0.85x | 1.15x | 1.32x | 1.20x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ZBH stock.
Zimmer Biomet Holdings, Inc. (ZBH) generated $1.70B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Zimmer Biomet Holdings, Inc. (ZBH) generated $1.47B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Zimmer Biomet Holdings, Inc. (ZBH) spent $224.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Zimmer Biomet Holdings, Inc. (ZBH) returned $190.3M to shareholders via cash dividends and spent $487.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Volatile working capital and conversion
Metrics are mathematically derived from official filings.
Operating Cash Flow Far Exceeds Reported Earnings
According to reported quarterly figures, ZBH's operating cash flow has run at roughly 1.5 to 3.7 times net income over the last ten quarters, a gap that suggests earnings are conservatively measured relative to cash generation, though the ratio is sensitive to working capital swings.
The consistently elevated ratio of operating cash flow to net income, with the most recent quarters at 2.92 and 2.26, suggests substantial non-cash charges such as the roughly $270 to $280 million of quarterly depreciation and amortization are depressing reported earnings. The magnitude of the gap warrants caution, however, because the ratio swings sharply with working capital movements, as the 3.71 reading in Q4 2025 was driven in part by a $158.6 million working capital inflow. Investors should monitor whether conversion holds once working capital normalizes.
Free Cash Flow Margins Remain Volatile
Based on reported figures, ZBH's free cash flow margin ranged from 11.5% to 29.8% across the last ten quarters, with the latest reading of 18.1% indicating that cash generation has not yet settled into a stable trajectory.
The wide swing in free cash flow margin, from a low of 11.5% in Q2 2024 to a peak near 30% in Q4 2025, appears to reflect timing of working capital and capital expenditures rather than a clear structural trend. The decline from the Q4 2025 peak to 18.1% in the latest quarter may suggest that the prior period benefited from one-time working capital release. Stakeholders should treat the current run rate as uncertain until multiple quarters confirm a stable level.
Working Capital Drives Quarterly Cash Variability
As reported in the quarterly statements, ZBH's working capital changes swung from a $173.3 million outflow to a $158.6 million inflow within two quarters, indicating that collections, inventory, and payables timing is a dominant driver of reported cash flow.
The large swings in working capital, including the $173.3 million outflow in Q1 2026 and the $158.6 million inflow in Q4 2025, suggest that cash conversion is highly sensitive to the timing of receivables collection and inventory build. Given the company's heavy field inventory of implant sets, these swings may partly reflect consignment and placement dynamics. The data does not allow a definitive attribution, so the sources of these movements warrant further investigation.
Capital Spending Modest Relative to Revenue
Based on reported figures, ZBH's capital expenditures have generally run between 1.7% and 9.1% of revenue, with the most recent quarter at 9.1% representing a notable step-up from the low-single-digit intensity seen through most of the period.
Capital intensity has been low for most quarters, consistent with the company's reliance on existing manufacturing infrastructure, but the 9.1% level in Q3 2026 may indicate investment in robotic platforms or manufacturing capacity. Because depreciation of roughly $280 million per quarter far exceeds most capex readings, the company appears to be underinvesting relative to asset consumption in those periods, which may warrant monitoring. Whether the recent step-up reflects growth or maintenance spending cannot be determined from the provided data.
Acquisitions Absorb Excess Free Cash Flow
According to reported cash flow statements, ZBH's acquisition outflows totaled over $1.2 billion across several recent quarters, including $359.4 million in Q3 2026, suggesting that much of the free cash flow generated has been redeployed into M&A rather than retained or returned.
Dividends have been steady at roughly $46 to $49 million per quarter, a modest share of free cash flow, while buybacks have been intermittent and in some quarters large relative to the dividend. The heavy acquisition spending, including the $1.2 billion outflow in Q3 2025, suggests management is prioritizing inorganic growth over balance sheet accumulation. Investors should assess whether these acquisitions are generating returns that justify the capital committed, as the reported figures alone do not reveal their performance.
Cash Strength May Mask Structural Constraints
Based on reported figures, the strong operating cash flow ratios could overstate durable cash generation, since quarterly free cash flow has depended heavily on working capital timing and the 2026 quarters show a sharp drop from the Q4 2025 peak.
The bull case rests on operating cash flow running well above net income, yet several of the strongest quarters coincide with large working capital inflows that may not repeat, and depreciation of roughly $280 million per quarter is a recurring cost that limits how much of the gap represents true excess cash. Stated free cash flow also excludes acquisition outflows that have absorbed substantial capital, meaning that shareholder-available cash may be lower than headline figures suggest. These observations are inferences from the supplied quarterly data and do not establish a deterioration in underlying cash generation.